Drugs / Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05283395 | Mar 2022 → Mar 2023 | glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05283395 ↗ |
| Route | Topical | “one drop in each eye in the evening for 12 weeks” NCT05283395 ↗ |